Dr. Kumar’s Take
This is a historical review, not a clinical trial: George Nuki and Peter Simkin trace gout and hyperuricemia through the written medical record rather than testing a treatment in patients. Reading it, I am struck by how little the core clinical story has changed. Hippocrates tied podagra to an intemperate lifestyle in the fifth century BC, Galen linked it to debauchery and also recognized a hereditary trait, and the review describes the same dietary drivers, meat, seafood, and beer, behind the rise in gout today. The therapeutic arc is real progress: colchicine, then uricosuric agents, then xanthine oxidase inhibitors that lower plasma and urinary urate and can reverse tophaceous deposits. The behavioral advice, though, is essentially unchanged from antiquity.
Key Takeaways:
✔ Gout was first identified by the Egyptians in 2640 BC, and Hippocrates called podagra “the unwalkable disease” in the fifth century BC.
✔ Treatment history runs from colchicine, an alkaloid of the autumn crocus, to modern NSAIDs for acute gout and xanthine oxidase inhibitors for hyperuricemia.
✔ Antoni van Leeuwenhoek first described the crystals from a gouty tophus under the microscope in 1679, though their chemical composition was unknown at the time.
✔ Lifestyle, diet, and alcohol were as central in Hippocrates’ time as they are in today’s discussions of gout.
Actionable Tip
The review identifies excess dietary purines, derived from meat, seafood, and beer, as the dietary driver behind hyperuricemia and gout, and contrasts traditional Asian diets based on rice and vegetables, where gout has been relatively rare, with European and American diets high in meat and certain seafoods. If you are prone to gout or carry a high urate level, that contrast is the practical lever: less beer, less high-purine meat and seafood, more of a plant-and-grain-based pattern.
Brief Summary
“A Concise History of Gout and Hyperuricemia and Their Treatment” reviews the medical and cultural record of gout from ancient Egypt through the modern era. It traces the earliest Egyptian identification, Hippocrates’ aphorisms, Galen’s description of tophi as crystallized monosodium urate deposits, the medieval belief that an excess of one of the four humors would drop into a joint, and Thomas Sydenham’s classic account of a night-time attack seizing the great toe. Colchicine was used as a powerful purgative in ancient Greece more than 2,000 years ago, and its first use as a selective and specific treatment for gout is attributed to the Byzantine physician Alexander of Tralles in the sixth century AD. Uricosuric agents followed at the end of the 19th century. In the modern era NSAIDs are usually the drugs of choice for acute gout, and the authors call xanthine oxidase inhibitors perhaps the most important historical advance in treating hyperuricemia.
Study Design
This was a historical review, not a clinical trial and not a study in patients. The authors drew on historical medical writings and the published record, from Egyptian identification in 2640 BC through Hippocrates, Galen, Seneca, medieval humoral theory, Sydenham, van Leeuwenhoek’s microscopy, and the development of modern drug therapy. There is no enrolled population, no randomization, and no outcome data of the kind a trial would report.
Results
- Earliest descriptions: The Egyptians identified podagra in 2640 BC. Hippocrates recognized it in the fifth century BC and recorded aphorisms including that inflammation in gouty affections subsides within 40 days and that attacks become active in spring and autumn.
- A disease of the rich: Hippocrates called podagra an arthritis of the rich, as opposed to rheumatism, an arthritis of the poor. Because the associated lifestyle could historically only be afforded by the affluent, gout became known as the disease of kings.
- Naming: The Dominican monk Randolphus of Bocking, chaplain to the Bishop of Chichester (1197 to 1258), was the first to use the word gout for podagra. The term derives from the Latin gutta, or drop.
- First look at the crystals: Galen was the first to describe tophi, the crystallized monosodium urate deposits that can follow longstanding hyperuricemia. Van Leeuwenhoek, one of the pioneers of microscopy, described the long, transparent particles from a gouty tophus in 1679.
- Sex distribution: Gout has historically been considered a male disease. Seneca recorded gout in women during the reign of Nero, AD 54 to 68. It remains primarily a disease of men in middle age but has become more frequent in women, particularly after the menopause.
- Modern treatments: Colchicine, NSAIDs, uricosuric agents, and xanthine oxidase inhibitors, the last of which reduce plasma and urinary urate levels and have been shown to reverse the development of tophaceous deposits.
Why Uric Acid Causes Gout
Longstanding hyperuricemia allows monosodium urate to crystallize in tissue, and those deposits are what Galen described as tophi and what van Leeuwenhoek saw under his lens as long, transparent, pointed particles. The medieval explanation was humoral: an excess of one of the four humors was thought to drop into a joint and cause pain and inflammation. The modern explanation is chemical, and it is why the review treats xanthine oxidase inhibition, which lowers plasma and urinary urate, as the pivotal advance in managing hyperuricemia rather than only the acute attack.
Related Studies and Research
Cherries and Gout Prevention: Evaluates how cherry consumption affects the risk of recurrent gout flares.
Vitamin C and Uric Acid: Gout Study: Investigates whether vitamin C supplementation lowers uric acid.
Ancient Uricase and Evolutionary Loss: Explores the genomic and biochemical history of uric acid metabolism.
Podcast: How to Make Gout Disappear from Your Life: A comprehensive look at modern and ancient gout science, and how to beat it.
Frequently Asked Questions
Why was gout called the “disease of kings”?
Because it was associated with rich foods and excessive alcohol, a lifestyle that in the past only the affluent could afford. In some eras gout was even seen as socially desirable given its prevalence among the politically and socially powerful.
How did treatments for gout evolve?
Colchicine, from the autumn crocus, was used as a powerful purgative in ancient Greece more than 2,000 years ago, and Alexander of Tralles is credited with its first use as a specific gout treatment in the sixth century AD. Uricosuric agents arrived at the end of the 19th century. NSAIDs are now usually the drugs of choice for an acute attack, and xanthine oxidase inhibitors are used to lower urate.
Is gout really increasing today?
Yes. Increasing affluence has expanded the number of people following a westernized diet and lifestyle, and the review notes this has been paralleled by a rise in the incidence and prevalence of gout worldwide.
Can genetics cause gout?
The review notes that Galen, while linking gout to debauchery and intemperance, also recognized a hereditary trait, one the Roman senator Seneca had referred to earlier.
Conclusion
Gout is among the earliest diseases recognized as a clinical entity, described in Egypt in 2640 BC and clinically characterized by Hippocrates 2,500 years ago in terms that still hold. What has changed is who gets it: once a marker of wealth, it now follows the spread of a westernized diet. What has not changed is the lever. Diet and alcohol sat at the center of the story in the fifth century BC, and they sit there still, alongside drugs that can lower urate and clear tophi.
